Moderate Evidence
Research Overview
CT-388 Research for Metabolic Syndrome
An evidence-based overview of research examining CT-388 in the context of metabolic syndrome. This page synthesizes findings from peer-reviewed literature.
Research Summary
Dual incretin agonists like CT-388 address multiple components of metabolic syndrome including obesity, insulin resistance, and dyslipidemia. The direct effects on adipose tissue via GIP receptors may provide benefits beyond weight loss alone.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Metabolic Syndrome
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. CT-388 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.